Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Permethrin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Winicker Norimed GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapy for Scabies With Two Differently Concentrated Permethrin Creams
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : Permethrin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Winicker Norimed GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the proprietary SODAS® technology.
Product Name : Ritalin LA
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the SODAS (Spheroidal Oral Drug Absorption System...
Product Name : Ritalin LA
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Cosmo Pharmaceuticals
Deal Size : $4.4 million
Deal Type : Licensing Agreement
Cosmo and Infectopharm Sign License for Winlevi® in Germany, Italy, and Austria
Details : Under the license agreement terms, Infectopharm will receive from Cosmo, the exclusive right to commercialize Winlevi (clascoterone) in Germany, Italy & Austria, which is indicated for acne vulgaris.
Product Name : Winlevi
Product Type : Other Small Molecule
Upfront Cash : $0.9 million
April 10, 2022
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Cosmo Pharmaceuticals
Deal Size : $4.4 million
Deal Type : Licensing Agreement
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : GKM Gesellschaft für Therapieforschung
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : GKM Gesellschaft für Therapieforschung
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Permethrin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Winicker Norimed GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)
Details : Undisclosed
Product Name : InfectoScab
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2021
Lead Product(s) : Permethrin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Winicker Norimed GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sanacutan Basiscreme
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Gesellschaft für Therapieforschung mbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Sanacutan Basiscreme
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Gesellschaft für Therapieforschung mbH
Deal Size : Inapplicable
Deal Type : Inapplicable